SynthesisPharmacoEconomics2013
Cost of illness in colorectal cancer: an international review.
Synthesis in PharmacoEconomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03965325 (FOcUs on Colorectal CAncer oUtcomes), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FOcUs on Colorectal CAncer oUtcomes: Long-Term Study
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Irritable Bowel Syndrome Is Not Associated with an Increased Risk of Polyps and Colorectal Cancer: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2023Pooled it
- Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Cost-of-illness studies for bipolar disorder: systematic review of international studies.PharmacoEconomics · 2015Pooled it
- Analysis of the Direct Medical Costs of Colorectal Cancer in Antigua and Barbuda: A Prevalence-Based Cost-of-Illness Study.International journal of environmental research and public health · 2025Article
- Colorectal cancer-related resource utilization and healthcare costs in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Cost of illness for colorectal cancer in Japan - a time trend and future projections (1996-2035) based on governmental statistics.BMC health services research · 2023Article
- Treatment Costs of Colorectal Cancer by Sex and Age: Population-Based Study on Health Insurance Data from Germany.Cancers · 2022Article
- Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.Journal of the National Cancer Institute. Monographs · 2022Review
- First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan.International journal of environmental research and public health · 2021Article
- Resource Use and Costs Associated to the Initial Phase of Treatment for Patients with Colorectal Cancer Receiving Post-Surgery Chemotherapy: A Cost Analysis from a Healthcare Perspective.Iranian journal of public health · 2021Article
- Cost-of-illness studies in rare diseases: a scoping review.Orphanet journal of rare diseases · 2021Article
- Barriers of colorectal cancer screening test among adults in the Saudi Population: A Cross-Sectional study.Preventive medicine reports · 2020Article
- Till death do us part: the effect of marital status on health care utilization and costs at end-of-life. A register study on all colorectal cancer decedents in Norway between 2009 and 2013.BMC health services research · 2020Article
- A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries.Frontiers in public health · 2020Article
- Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report.Frontiers in pharmacology · 2019Article
- First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs.International journal of colorectal disease · 2018Review
- Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs.International journal of colorectal disease · 2018Article
- Prokineticin 2 expression as a novel prognostic biomarker for human colorectal cancer.Oncotarget · 2018Article
- High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer.Oncology letters · 2018Article
- Correlations between TBL1XR1 and recurrence of colorectal cancer.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGiven the current-and increasing-pressure to limit expenditure on health care provision in many countries, a better understanding of the cost burden of colorectal cancer is needed. Cost-of-illness studies and reviews thereof can be a useful tool for analysing and critically evaluating the cost-related development of colorectal cancer, and they highlight important cost drivers.
methodsA systematic review was conducted from 2002 to 2012 to identify cost-of-illness studies related to colorectal cancer, searching the Medline, PubMed, Science Direct, Cochrane Library and the York CRD databases.
resultsAmong the 10 studies (from France, the US, Ireland and Taiwan) included in the review, 6 studies reported prevalence-based estimates and 4 studies focussed on incidence-based data. In the studies included in the review, long-term costs for colorectal cancer of up to $50,175 per patient (2008 values) were estimated. Most of the studies in the review showed that the initial and terminal phases of colorectal cancer care are the most expensive, with continuing treatment being the least costly phase. One study also highlighted that stage I CRC disease was the least costly and stage III the most costly of all 4 stages, due to the high cost impact of biological agents.
conclusionsThis review has highlighted a trend for rising costs associated with CRC, which is linked to the increasing use of targeted biological therapies. COI studies in colorectal cancer can identify specific components and areas of care that are especially costly, thereby focussing attention on more cost-effective approaches, which is especially relevant to the increased use of biological agents in the field of personalised medicine. COI studies are an important tool for further health economic evaluations of personalised medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.